Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Pasireotide | Pasireotide pamoate, also known as SOM230, is an orphan drug approved for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. Synonyms: Pasireotide; SOM230; SOM-203; SOM 203; Signifor. Grade: >98%. CAS No. 396091-73-9. Molecular formula: C58H66N10O9. Mole weight: 1047.227. |  |
| Pasireotide | Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5 , pK i =8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity [1] [2] [3]. Uses: Scientific research. Group: Peptides. Alternative Names: SOM230. CAS No. 396091-73-9. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-16381. |  |
| Pasireotide acetate | Pasireotide acetate is a cyclic peptide, which can improve agonist activity at somatostatin receptors. Synonyms: Pasireotide acetate salt; SOM230 acetate. Grade: 98%. CAS No. 396091-76-2. Molecular formula: C60H70N10O11. Mole weight: 1107.26. | |
| Pasireotide acetate | Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5 , pK i =8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity [1] [2] [3]. Uses: Scientific research. Group: Peptides. Alternative Names: SOM230 acetate. CAS No. 396091-76-2. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-16381A. | |
| Pasireotide Diaspartate | Pasireotide is an orphan drug approved for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It is a somatostatin receptor (SSTR) agonist with selectively for SST1, SST2, SST3, and SST5 over SST4 (IC50s = 9.3, 1, 1.5, 0.16, and >100 nM, respectively, for human recombinant receptors). Uses: Hormones. Synonyms: SOM230. Grade: ≥95%. CAS No. 820232-50-6. Molecular formula: C58H66N10O9ยท2C4H7NO4. Mole weight: 1313.41. | |
| Pasireotide ditrifluoroacetate | Pasireotide, also known as SOM230, is an orphan drug approved for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. Synonyms: Pasireotide TFA salt; SOM230 TFA salt; SOM-230 TFA salt; SOM 230 TFA salt; SOM230 ditrifluoroacetate; SOM-230 ditrifluoroacetate; SOM 230 ditrifluoroacetate. Molecular formula: C62H68F6N10O13. Mole weight: 1275.3. | |
| Pasireotide L-aspartate salt | Pasireotide is a synthetic long-acting cyclic hexapeptide exhibits unique high-affinity binding to human somatostatin receptors. Uses: High-affinity binding to human somatostatin receptors. Synonyms: cyclo((4R)-4-(2-Aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-) L-aspartate salt. Grade: ≥98%. CAS No. 396091-77-3. Molecular formula: C62H73N11O13. Mole weight: 1180.31. | |
| Pasireotide pamoate | Pasireotide, also known as SOM230, is an orphan drug approved for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. Synonyms: Pasireotide embonate; SOM230 pamoate; SOM-230 pamoate; SOM 230 pamoate. CAS No. 396091-79-5. Molecular formula: C81H82N10O15. Mole weight: 1435.6. | |
Our database is helping our users find suppliers everyday.
